- Welcome to the Institute's new Internet
- Stem cell technique offers new potential to treat blindness
- 20% of adult obesity might be caused by infant nutrition
- Study to reduce birth defects
- Beta thalassaemia gene therapy success
- Genetic link with human male infertility identified
- New research into Congenital Toxoplasmosis endorses UK health guidance for pregnant women
- ICH Poster Competition and Open Day
- Is 'breast only' for first six months best?
- Six months of exclusive breast feeding: how good is the evidence?
- Major new programme to tackle childhood obesity launched
- Study shows that early detection of Severe Combined Immunodeficiency would save lives
- £28 Million boost to understand child health
- The impact of sex selection and abortion in China, India and South Korea
- Regenerative medicine success for muscles
- New study examines early-onset eating disorders in under-13s
- International 50-year mortality trends in children and young people reveal an inadequate response to the health problems and causes of death in adolescents, particularly young men
- Apples, oranges and jam – the tasty way to keep kidney disease at bay
- Scientists prove heart has built-in repair mechanism: Exciting breakthrough towards mending broken hearts
- Fight for Sight awards £1 million for retinal disease research
- New Policy Research Unit in the Health of Children, Young People and Families
- UCLB and NCYPE announce a commercialisation agreement with Special Products Limited for Epistatus®
- Molecular scalpel hope for Duchenne muscular dystrophy
- Eating disorders linked to fertility problems and negative feelings towards pregnancy
- Science: From Cradle to Grave
- £36 million boost for children's health research
- Gene therapy success for children born without functioning immune system
- ICH Open Day 2011
- Under 16s make up less than one per cent of NHS patient surveys
- Mitochondria genes and cardiomyopathy
- Child Health Research PhD Studentships 2012-13
- Tate Liverpool exhibition inspires pioneering science games
- No consistent decrease in child maltreatment despite years of policy initiatives designed to achieve it
- New approach on bone marrow transplant infections
- Genetic testing for antibiotic related deafness
- Great Ormond Street Hospital Children’s Charity announces plans to build a Centre for Children’s Rare Disease Research
- Gene therapy shows clinical effect in third immune disease
- Clean delivery kits linked to substantial reduction in neonatal deaths in South Asia, study shows
- Genetic variant inherited from the mother significantly increases birth weight
- Not enough is known about prescription drug use in pregnancy, say experts
- Improving access to education and employment and reducing the risk of transport-related injury are among the best ways to improve adolescent health
- Research reveals association between red hair gene and rare birthmarks
- Five new UCL fellows of Academy of Medical Sciences
- Surgery boost for children with drug-resistant epilepsy.
- Professor of economics and deputy director appointed to the new UK Birth Cohort Study
- First example of a heritable abnormality affecting semantic cognition found
- New Director of the UCL Institute of Child Health
- New approach to recording suspected child abuse in patient records
- Amniotic fluid yields alternatives to embryonic stem cells
- ICH OPEN DAY AND POSTER COMPETITION
- Europe’s first research centre to battle birth defects
- New cause of thyroid hormone deficiency discovered
- £10 million boost for Centre for Children’s Rare Disease Research
- EU awards grant to develop new drug for Duchenne muscular dystrophy
- New research centre for teenagers with arthritis
- Major study shows steep decline in figure for diagnosed epilepsy
- Obesity leads to vitamin D deficiency
Not enough is known about prescription drug use in pregnancy, say experts
30 March 2012
Prescription drug use during pregnancy is prevalent, however, not enough is known about the adverse effects they may have on the developing fetus, concludes a new review published in The Obstetrician & Gynaecologist (TOG) today.
The majority of women take prescriptions for pregnancy-related complaints and minor infections. However, a small proportion of women receive medication for treatment for chronic diseases such as asthma, depression or hypertension.
The prevalence of congenital malformations is estimated at 2–3% of all births, of which approximately 1% are considered attributable to prescription drug use during pregnancy, states the review.
Two common groups of drugs, anti-epileptics and antidepressants are explored in the review.
Anti-epileptic drugs (AEDs) are the most studied group of drugs in pregnancy, with an estimated 1 in 250 pregnancies exposed.
National Institute for Health and Clinical Excellence (NICE) guidelines state that it is not possible to comment on the risks of physical abnormalities from the drugs in view of the limited data available.
The review also looks at preliminary data collated from the UK Epilepsy and Pregnancy Register which found that the risk of congenital malformations with the use of one AED was 3.7% (n = 2598), compared with 6.0% (n = 770) in those women taking two or more AEDs.
Up to 4% of women use antidepressants during pregnancy, with 2.3% taking selective serotonin reuptake inhibitors (SSRIs).
A large birth defect registry study found no association between maternal SSRI use and cardiac malformations. However, the review states that antidepressant use in late pregnancy is associated with neonatal complications such as premature birth, feeding problems, respiratory distress syndrome, endocrine and metabolic disorders and temperature regulation disorders.
The review concludes that our evidence base for using prescription drugs in pregnancy remains limited and that drug companies do not recruit pregnant women to their clinical trials unless the drug in question is aimed at pregnancy-related disease.
Alastair Sutcliffe, Senior Lecturer in Child Health, UCL Institute of Child Health and co-author of the review said:
“Many pregnant women use prescription drugs, however, the risk to the fetus remains unknown.
“Pregnant women are excluded from clinical trials which means when new drugs are released there is almost no information on their safety and efficacy in pregnancy.”
TOG’s Editor –in-Chief, Jason Waugh said:
“The maternal physiological changes that occur during pregnancy can alter what the body does to the drug in some cases. More research is needed into the fetal effects of some drugs as there are big gaps in our knowledge.”
Page last modified on 30 mar 12 14:38